Toxicity of clopidogrel and ticlopidine on human myeloid progenitor cells: Importance of metabolites

Toxicology

Volumn 299, Issue 2-3, 2012, Pages 139-145

  Maseneni, Swarna ^a,b   Donzelli, Massimiliano ^a,b   Taegtmeyer, Anne Barbara ^a   Brecht, Karin ^a,b   Krähenbühl, Stephan ^a,b,c  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

^c Swiss Centre for Applied Human Toxicology   (Switzerland)

Author keywords

Clopidogrel; Clopidogrel carboxylate; Myeloperoxidase; Myelotoxicity; Ticlopidine

Indexed keywords

CLOPIDOGREL; CLOPIDOGREL CARBOXYLATE; CYTOCHROME P450 3A4; DRUG METABOLITE; MYELOPEROXIDASE; TICLOPIDINE; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW TOXICITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DEGRADATION; DRUG EFFECT; ENZYME ACTIVITY; GRANULOCYTE; HUMAN; HUMAN CELL; MYELOID PROGENITOR CELL; PRIORITY JOURNAL;

CELL SURVIVAL; COLONY-FORMING UNITS ASSAY; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MYELOID PROGENITOR CELLS; PEROXIDASE; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 84862861239     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2012.05.017     Document Type: Article

References (34)

1. Akcay A., Kanbay M., Agca E., Sezer S., Ozdemir F.N. Neutropenia due to clopidogrel in a patient with end-stage renal disease. Ann. Pharmacother. 2004, 38:1538-1539.
2. Bieche I., Narjoz C., Asselah T., Vacher S., Marcellin P., Lidereau R., Beaune P., de Waziers I. Reverse transcriptase-PCR quantification of mRNA levels from cytochrome (CYP)1 CYP2 and CYP3 families in 22 different human tissues. Pharmacogenet. Genomics 2007, 17:731-742.
3. CAPRIE-Steering-Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE) CAPRIE Steering Committee. Lancet 1996, 348:1329-1339.
4. Clarke T.A., Waskell L.A. The metabolism of clopidogrel is catalyzed by human cytochrome P450 3A and is inhibited by atorvastatin. Drug Metab. Dispos. 2003, 31:53-59.
5. Dalvie D.K., O'Connell T.N. Characterization of novel dihydrothienopyridinium and thienopyridinium metabolites of ticlopidine in vitro: role of peroxidases, cytochromes p450, and monoamine oxidases. Drug Metab. Dispos. 2004, 32:49-57.
6. Farid N.A., Payne C.D., Small D.S., Winters K.J., Ernest C.S., Brandt J.T., Darstein C., Jakubowski J.A., Salazar D.E. Cytochrome P450 3A inhibition by ketoconazole affects prasugrel and clopidogrel pharmacokinetics and pharmacodynamics differently. Clin. Pharmacol. Ther. 2007, 81:735-741.
7. Farid N.A., Kurihara A., Wrighton S.A. Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans. J. Clin. Pharmacol. 2010, 50:126-142.
8. Goyal R.K., Srivastava D., Lessnau K.D. Clopidogrel-induced hepatocellular injury and cholestatic jaundice in an elderly patient: case report and review of the literature. Pharmacotherapy 2009, 29:608-612.
9. Kazui M., Nishiya Y., Ishizuka T., Hagihara K., Farid N.A., Okazaki O., Ikeda T., Kurihara A. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab. Dispos. 2010, 38:92-99.
10. Klebanoff S.J., Olszowski S., Van Voorhis W.C., Ledbetter J.A., Waltersdorph A.M., Schlechte K.G. Effects of gamma-interferon on human neutrophils: protection from deterioration on storage. Blood 1992, 80:225-234.
11. Liu Z.C., Uetrecht J.P. Metabolism of ticlopidine by activated neutrophils: implications for ticlopidine-induced agranulocytosis. Drug Metab. Dispos. 2000, 28:726-730.
12. Mizushima M., Iwata N., Fujimoto T.T., Ishikawa K., Fujimura K. Patient characteristics in ticlopidine hydrochloride-induced liver injury: case-control study. Hepatol. Res. 2005, 33:234-240.
13. Nishimura M., Naito S., Yokoi T. Tissue-specific mRNA expression profiles of human nuclear receptor subfamilies. Drug Metab. Pharmacokinet. 2004, 19:135-149.
14. Ono K., Kurohara K., Yoshihara M., Shimamoto Y., Yamaguchi M. Agranulocytosis caused by ticlopidine and its mechanism. Am. J. Hematol. 1991, 37:239-242.
15. Pereillo J.M., Maftouh M., Andrieu A., Uzabiaga M.F., Fedeli O., Savi P., Pascal M., Herbert J.M., Maffrand J.P., Picard C. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab. Dispos. 2002, 30:1288-1295.
16. Pessina A., Albella B., Bueren J., Brantom P., Casati S., Gribaldo L., Croera C., Gagliardi G., Foti P., Parchment R., Parent-Massin D., Sibiril Y., Van Den Heuvel R. Prevalidation of a model for predicting acute neutropenia by colony forming unit granulocyte/macrophage (CFU-GM) assay. Toxicol In Vitro 2001, 15:729-740.
17. Pichler W.J. Immune mechanism of drug hypersensitivity. Immunol. Allergy Clin. North Am. 2004, 24:373-397. v-vi.
18. Pincemail J., Deby C., Thirion A., de Bruyn-Dister M., Goutier R. Human myeloperoxidase activity is inhibited in vitro by quercetin. Comparison with three related compounds. Experientia 1988, 44:450-453.
19. Quinn M.J., Fitzgerald D.J. Ticlopidine and clopidogrel. Circulation 1999, 100:1667-1672.
20. Rajandram R.K., Ramli R., Karim F., Rahman R.A., Fun L.C. Necrotizing gingivitis: a possible oral manifestation of ticlopidine-induced agranulocytosis. N. Z. Med. J. 2007, 120:U2590.
21. Saltiel E., Ward A. Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states. Drugs 1987, 34:222-262.
22. Savi P., Pereillo J.M., Uzabiaga M.F., Combalbert J., Picard C., Maffrand J.P., Pascal M., Herbert J.M. Identification and biological activity of the active metabolite of clopidogrel. Thromb. Haemost. 2000, 84:891-896.
23. Savi P., Labouret C., Delesque N., Guette F., Lupker J., Herbert J.M. P2y(12), a new platelet ADP receptor, target of clopidogrel. Biochem. Biophys. Res. Commun. 2001, 283:379-383.
24. Schomig A., Neumann F.J., Kastrati A., Schuhlen H., Blasini R., Hadamitzky M., Walter H., Zitzmann-Roth E.M., Richardt G., Alt E., Schmitt C., Ulm K. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N. Engl. J. Med. 1996, 334:1084-1089.
25. Skurnik Y.D., Tcherniak A., Edlan K., Sthoeger Z. Ticlopidine-induced cholestatic hepatitis. Ann. Pharmacother. 2003, 37:371-375.
26. Symeonidis A., Kouraklis-Symeonidis A., Seimeni U., Galani A., Giannakoulas N., Fragopanagou E., Tiniakou M., Matsouka P., Zoumbos N. Ticlopidine-induced aplastic anemia: two new case reports, review, and meta-analysis of 55 additional cases. Am. J. Hematol. 2002, 71:24-32.
27. Talakad J.C., Shah M.B., Walker G.S., Xiang C., Halpert J.R., Dalvie D. Comparison of in vitro metabolism of ticlopidine by human cytochrome P450 2B6 and rabbit cytochrome P450 2B4. Drug Metab. Dispos. 2011, 39:539-550.
28. Taubert D., Kastrati A., Harlfinger S., Gorchakova O., Lazar A., von Beckerath N., Schomig A., Schomig E. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb. Haemost. 2004, 92:311-316.
29. Uz O., Kardesoglu E., Aparci M., Yiginer O., Isilak Z., Ozmen N. Nonfatal aplastic anemia associated with clopidogrel. Anadolu Kardiyol. Derg. 2010, 10:291.
30. Waldhauser K.M., Torok M., Ha H.R., Thomet U., Konrad D., Brecht K., Follath F., Krahenbuhl S. Hepatocellular toxicity and pharmacological effect of amiodarone and amiodarone derivatives. J. Pharmacol. Exp. Ther. 2006, 319:1413-1423.
31. Wiper A., Schmitt M., Roberts D.H. Clopidogrel-induced hepatotoxicity. J. Postgrad. Med. 2008, 54:152.
32. Yoneda K., Iwamura R., Kishi H., Mizukami Y., Mogami K., Kobayashi S. Identification of the active metabolite of ticlopidine from rat in vitro metabolites. Br. J. Pharmacol. 2004, 142:551-557.
33. Yusuf S., Zhao F., Mehta S.R., Chrolavicius S., Tognoni G., Fox K.K. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 2001, 345:494-502.
34. Zahno A., Brecht K., Bodmer M., Bur D., Tsakiris D.A., Krahenbuhl S. Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro. Br. J. Pharmacol. 2010, 161:393-404.